Pomerantz Law Firm Issues Investor Alert on Class Action Against Viatris, Inc. Amid Concerns of Securities Fraud

Pomerantz Law Firm Announces Class Action Lawsuit Against Viatris, Inc.

On May 26, 2025, Pomerantz LLP, a prominent law firm specializing in class action litigation, announced that it has initiated a class action lawsuit against Viatris, Inc. (NASDAQ: VTRS). This legal action has surfaced amidst significant concerns about potential securities fraud and other unlawful business practices conducted by Viatris and some of its executives or directors. As investors are now urged to take action, the upcoming deadlines loom, adding urgency to the matter.

Pomerantz Law Firm is advising investors who suffered losses in their stakes with Viatris to contact Danielle Peyton at the firm— either through email or telephone. Those interested in participating in the case are encouraged to provide their contact details, including mailing address, phone number, and the number of shares they purchased during the class period. The deadline for filing a motion to be appointed as Lead Plaintiff is set for June 3, 2025.

The class action stems from unresolved issues that arose following Viatris's financial disclosures on February 27, 2025. During this announcement, the company reported its fourth quarter and overall 2024 results, which fell short of the consensus estimates on critical financial metrics. Additionally, the company offered a lower-than-anticipated guidance for its performance in 2025, raising alarms among investors.

“My investment was based on optimistic forecasts that quickly turned sour,” remarked one affected investor who requested to remain anonymous. “I never thought that I would find myself entangled in a situation like this, where the integrity of the company's leadership is called into question.”

In a further escalation of the situation, Viatris has been under scrutiny due to recent updates regarding a manufacturing facility in India. Following a warning letter and subsequent import alert issued by the U.S. Food and Drug Administration (FDA), Viatris reported that it is in the midst of remediation efforts at the facility. The firm asserted that they are making substantial progress and anticipate completion within a few months, at which point the company plans to request a reinspection from the FDA.

However, following these revelations, Viatris’s stock experienced a dramatic decline, plummeting $1.71 or 15.21%, to close at $9.53 on the same day as the disclosures. Investors are understandably anxious as they try to decipher the implications of these events on their investments.

Pomerantz Law Firm has a longstanding reputation in the field of corporate, securities, and antitrust class litigation. Founded by the esteemed Abraham L. Pomerantz, known as the dean of the class action bar, the firm has remained dedicated to upholding the rights of those affected by fraudulent practices and breaches of fiduciary duties in the corporate sphere. Over its 85-year history, Pomerantz has successfully fought for numerous victims, recovering multi-million dollar damages on behalf of class members.

As this class action progresses, concerned investors are reminded to stay informed and consider taking action. The financial landscape can be volatile, and situations like this underscore the importance of vigilance and due diligence when selecting investment opportunities.

For more details regarding the class action, including a copy of the complaint, individuals should visit Pomerantz Law Firm’s website.

Note: This article contains information provided for educational purposes only and does not constitute legal advice. Interested parties should contact the Pomerantz Law Firm for proper representation and guidance. Investors are reminded that prior results do not guarantee similar outcomes in future cases.